Pharmacyclics price target raised to $113 from $95 at Bernstein Bernstein believes that there are several drivers of revenue growth for B cell malignancies treatments including those developed by Pharmacyclics. The firm predicts that the chronic lymphocytic leukemia market will jump to $5.7B in 2018 from $1.3B today, with Pharmacyclics' ibrutinib dominating that market "for some years." However, it keeps a Market Perform rating on Pharmacyclics.
News For PCYC From The Last 14 Days
Check below for free stories on PCYC the last two weeks.